{{Rsnum
|rsid=2229107
|Gene=ABCB1
|Chromosome=7
|position=87509343
|Orientation=plus
|GMAF=0.01837
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;T)
|geno3=(T;T)
|Gene_s=ABCB1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;T)
| geno3=(T;T)
| CEU | 0.0 | 0.0 | 100.0
| HCB | 0.0 | 0.0 | 100.0
| JPT | 0.0 | 0.0 | 100.0
| YRI | 1.4 | 12.2 | 86.4
| ASW | 0.0 | 10.5 | 89.5
| CHB | 0.0 | 0.0 | 100.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 1.8 | 12.7 | 85.5
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 12.9 | 87.1
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2229107
|Name_s=ABCB: S1141T
|Gene_s=ABCB1
|Feature=Exon/NonSyn
|Evidence=PubMed ID:19940846
|Annotation=Increased resistance to daunorubicin, doxorubicin, valinomycin, or actinomycin D in transformed yeast
|Drugs=daunorubicin; doxorubicin; valinomycin
|Drug Classes=ACTINOMYCINES
|Diseases=
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA165111603
}}

{{GET Evidence
|gene=ABCB1
|aa_change=Ser1141Thr
|aa_change_short=S1141T
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2229107
|overall_frequency_n=223
|overall_frequency_d=10758
|overall_frequency=0.0207288
|n_genomes=4
|n_genomes_annotated=0
|n_haplomes=4
|n_articles=1
|n_articles_annotated=1
|in_pharmgkb=Y
|nblosum100=-2
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}